Investigational drug · Phase 2
LAD603
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alopecia Areata.
Phase 2Last checked: Nov 19, 2026Latest source record: May 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "LAD603"
First trial start
2025
Dec 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LAD603", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alopecia Areata
Approved drugs for the same conditions: Alopecia areata · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "LAD603" as an intervention, largest first.
- A Study of LAD603 in Adults With Alopecia AreataPivotal-lookingRecruiting
Almirall, S.A.Industry
NCT07311564 · 136 participants (planned) · Start Dec 17, 2025 · Primary completion Jun 23, 2027
Drug: LAD603 · For: Alopecia Areata
Sites: Omaha, Nebraska
Almirall, S.A.Industry
NCT06200597 · 92 participants · Start Dec 5, 2023 · Primary completion May 11, 2025
Drug: LAD603 · For: Healthy Volunteers
Sites: Lenexa, Kansas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Alopecia Areata
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
- RezpegaldesleukinNKTR-358, REZPEGPhase 34 trials
Nektar Therapeutics · Moderate-to-Severe Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Alopecia Areata
- CTP-543Phase 31 trial
Sun Pharmaceutical Industries, Inc. · Alopecia Areata
- ADX-914bempikibartPhase 22 trials
Q32 Bio Inc. · Atopic Dermatitis, Alopecia Areata
- LY4005130Phase 22 trials
Eli Lilly · Alopecia Areata, Vitiligo, Non-Segmental Vitiligo (NSV)
- NXC736Phase 21 trial
NEXTGEN Bioscience · Alopecia Areata
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.